---
title: "FDA approves Roche’s Wilserdly (giredestrant) for ESR1-mutant HR-positive, HER2-negative breast ca"
id: "stat-news-0-stat-fda-approves-new-breast-cancer-drug-providing-new-option-for-some-patients"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-0-stat-fda-approves-new-breast-cancer-drug-providing-new-option-for-some-patients"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/11/16/fda-approves-new-roche-breast-cancer-drug/?utm_campaign=rss"
published_at: "2026-11-16T20:56:47.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# FDA approves Roche’s Wilserdly (giredestrant) for ESR1-mutant HR-positive, HER2-negative breast ca
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-0-stat-fda-approves-new-breast-cancer-drug-providing-new-option-for-some-patients
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/11/16/fda-approves-new-roche-breast-cancer-drug/?utm_campaign=rss)
- **Published At:** 2026-11-16T20:56:47.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The FDA granted approval to Wilserdly (giredestrant), an oral **selective estrogen receptor degrader** (SERD), for a defined subgroup of advanced breast cancer patients. - Approval covers patients with **HR-positive**, **HER2-negative** advanced breast cancer whose tumors harbor an **ESR1** mutation, a genomic marker linked to resistance to standard endocrine therapies. - The decision was supported by results from the evERA trial, which investigators reported showed an extension in the time before tumors progressed (the source described an improvement in progression timing but did not provide numerical estimates or statistical details). - Roche publicly stated the medicine could become one of the company’s highest-selling products; the source noted the company’s belief but said external estimates vary and did not provide specific sales forecasts. - The therapy is oral and classified as a SERD; the source did not report dosing, schedule, safety profile details, or full trial methodology such as sample size, primary endpoints, or p-values. - The approval gives Roche renewed presence in breast cancer after its historical role with Herceptin; the source pointed to that corporate context without listing competitive products or market-share data. - STAT reported the core regulatory decision and trial headline result but placed the remaining article content behind its STAT+ subscription paywall; the source did not disclose regulatory review timelines or label language beyond the indicated patient population. - Unanswered items in the public report include granular evERA outcomes, adverse-event rates, comparative efficacy metrics, and postmarketing requirements, none of which were provided in the source article. - The report originated from STAT Europe correspondent Andrew Joseph and was published on Nov. 16, 2026; the article emphasized the approval as an important regulatory milestone for Roche. - Investigators and the study team were cited in general terms; the source did not quote specific clinicians, regulatory officers, or trial investigators on the record with detailed commentary.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/11/16/fda-approves-new-roche-breast-cancer-drug/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/11/16/fda-approves-new-roche-breast-cancer-drug/?utm_campaign=rss) [Clinical trials](https://www.statnews.com/topic/clinical-trials/) [Cancer](https://www.statnews.com/topic/cancer/) [health care](https://www.statnews.com/topic/health-care/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [Midterms 2026](https://www.statnews.com/midterms-2026-health-care-policy-issues/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Trust in Science](https://www.statnews.com/trust-in-science/) * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Madness 2027](https://www.statnews.com/feature/stat-madness/apply/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) China's Biotech Powerhouse 25 We ranked the 25 most valuable publicly traded Chinese drugmakers [ See the list ](https://www.statnews.com/china-biotech-index-powerhouse-25/) [STAT Plus](https://www.statnews.com/stat-plus/)[Pharma](https://www.statnews.com/category/pharma/) # FDA approves new breast cancer drug, providing new option for some patients, boost for Roche ## Company believes therapy could become its top-selling product, though estimates vary * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/11/16/fda-approves-new-roche-breast-cancer-drug/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2026/11/GettyImages-2286590067-645x645.jpg) Xavier GALIANA/AFP via Getty Images ![](https://www.statnews.com/wp-content/uploads/2021/02/andrew-j-avatar-small-1-80x80.png) By [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) Nov. 16, 2026 Europe Correspondent ![](https://www.statnews.com/wp-content/uploads/2021/02/andrew-j-avatar-small-1-80x80.png) [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) 1. [](https://x.com/DrewQJoseph "X") andrew.joseph@statnews.com Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. The Food and Drug Administration on Monday approved a new breast cancer drug from Roche, teeing up the launch of a medicine that the Swiss company has said could become its top-selling product ever. The approval of Wilserdly, also known as giredestrant, was one of the most important regulatory decisions Roche had been awaiting. It also gives the company another foothold in breast cancer treatments, a field in which it has a storied history with the drug Herceptin through its subsidiary Genentech, though in recent years it’s fallen behind rival pharma companies in oncology. Advertisement The approval is specifically for patients with HR-positive, HER2-negative advanced breast cancer that has picked up a mutation in the ESR1 gene, a sign that the tumor is developing resistance to standard treatments. The evERA trial showed that the drug, an oral treatment known as a selective estrogen receptor degrader, or SERD, extended the time period before patients’ tumors progressed. STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [biotechnology](https://www.statnews.com/topic/biotechnology/), [Pharmaceuticals](https://www.statnews.com/topic/pharmaceuticals/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/andrew-j-avatar-small-1-80x80.png) [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) 1. [](https://x.com/DrewQJoseph "X") 2. Europe Correspondent 1. [](https://x.com/DrewQJoseph "X") 2. Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2024/03/Biotech-Scorecard-Logo-NoSTAT-640x290.png) ### STAT+ Newsletter Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_2158931352-80x80.jpeg) [Medical school should start after students take the Step 1 exam](https://www.statnews.com/2026/11/16/medical-school-step-1-exam-redesign-proposal/) 2. ![](https://www.statnews.com/wp-content/uploads/2020/07/AdobeStock_335879672-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Apple and OpenEvidence launch experimental health chat app](https://www.statnews.com/2026/11/15/apple-openevidence-launch-health-chat-app-experiment-ai/) 3. ![](https://www.statnews.com/wp-content/uploads/2017/01/AP80889059-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Federal judge issues final ruling blocking U.S. plan to limit visa length for grad students, postdocs](https://www.statnews.com/2026/11/16/judge-rejects-visa-limits-international-researchers-upholds-duration-of-status-policy/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_180917809-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence](https://www.statnews.com/2026/11/16/bladder-cancer-immunotherapy-reduced-tumor-recurrence-cg-oncology/) 5. ![](https://www.statnews.com/wp-content/uploads/2024/09/GettyImages-1237273640-1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics](https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/10/STATatHLTH_Wordpress_CalendarImage-80x80.jpg) STAT@hlth. A Dose of Reality on EHRs and AI In-person Nov 18 ](https://www.statnews.com/event/stathlth-a-dose-of-reality-on-ehrs-and-ai/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/2026ASH_Wordpress_CalendarImage-80x80.jpg) STAT@ASH: Medicine’s Bleeding Edge New Orleans, LA Dec 13 ](https://www.statnews.com/event/stat-at-ash-meeting-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/BTE2027_Wordpress_CalendarImage-80x80.jpg) 2027 Breakthrough Summit East New York City, NY Mar 18 ](https://www.statnews.com/event/2027-stat-breakthrough-summit-east/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_6400491-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA warns GLP-1 drugs carry potential risk of rare eye condition](https://www.statnews.com/2026/11/09/glp-1-drugs-potential-risk-rare-eye-condition-naion-fda/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_391451620_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug](https://www.statnews.com/pharmalot/2026/11/10/former-lilly-rep-claims-she-was-fired-for-complaining-about-marketing-of-mounjaro-diabetes-drug/) 3. ![](https://www.statnews.com/wp-content/uploads/2019/09/AP_060324030695-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA approves novel Bayer drug to reduce recurrence of stroke](https://www.statnews.com/2026/11/09/cardiovascular-stroke-recurrence-bayer-drug-fda-approval/) 4. ![](https://www.statnews.com/wp-content/uploads/2024/09/GettyImages-1237273640-1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics](https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/05/AP26023803702193-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say](https://www.statnews.com/2026/11/13/oura-acquisition-counsel-health-eli-lilly/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) In the Lab In the Lab November 16, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Federal judge issues final ruling blocking U.S. plan to limit visa length for grad students, postdocs ](https://www.statnews.com/2026/11/16/judge-rejects-visa-limits-international-researchers-upholds-duration-of-status-policy/) By [Anil Oza](https://www.statnews.com/staff/anil-oza/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharma Pharma November 16, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: In a win for MAHA, FDA creates new regulatory category for the supplement NAC ](https://www.statnews.com/2026/11/16/fda-proposes-new-category-supplement-nac/) By [Margaret Manto](https://www.statnews.com/staff/margaret-manto/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot November 16, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Expert warns of battleground over global access to newer GLP-1 drugs for obesity ](https://www.statnews.com/pharmalot/2026/11/16/semaglutide-obesity-glp1-access-medicines-low-income-countries/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Politics Politics November 16, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: NIAID acting head John Powers III appointed as the permanent director ](https://www.statnews.com/2026/11/16/john-powers-appointed-niaid-director/) By [Anil Oza](https://www.statnews.com/staff/anil-oza/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout The Readout November 16, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Biotech’s rebound isn’t lifting all boats equally ](https://www.statnews.com/2026/11/16/biotech-news-rebound-isnt-lifting-all-boats-equally/) By [Meghana Keshavan](https://www.statnews.com/staff/meghana-keshavan/) #### Subscriber Picks 1. ### [ A new tactic in the war over out-of-network bills: Health care providers are suing employers ](https://www.statnews.com/2026/11/11/no-surprises-act-phi-health-air-ambulance-sues-employers/) By [Bob Herman](https://www.statnews.com/staff/bob-herman/) 2. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: As Epic’s dominance grows, its iron grip is choking innovation in health technology ](https://www.statnews.com/2026/10/28/epic-systems-ehr-dominance-health-tech-antitrust-scrutiny/) By [Casey Ross](https://www.statnews.com/staff/casey-ross/) and [Brittany Trang](https://www.statnews.com/staff/brittany-trang/) 3. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug ](https://www.statnews.com/pharmalot/2026/11/10/former-lilly-rep-claims-s
## Related Clinical Research

- [NIH to relocate its last research chimpanzees to Chimp Haven sanctuary](https://medichelpline.com/clinical-feed/stat-news-1-stat-nih-to-move-last-group-of-its-research-chimps-to-a-sanctuary.md)
- [Medicare for More draws new attention in D.C. reporting](https://medichelpline.com/clinical-feed/stat-news-3-stat-medicare-for-more-gains-traction.md)
- [U.S. POINTER: Structured lifestyle program slows brain aging and cardiometabolic risk over 24 mont](https://medichelpline.com/clinical-feed/medical-news-today-0-combining-physical-mental-and-social-habits-slows-brain-aging-in-2-year-trial.md)
- [Ultra-processed foods linked to MRI signs of vascular brain injury in middle-aged adults](https://medichelpline.com/clinical-feed/medical-news-today-0-ultra-processed-foods-may-be-harming-brain-health-in-otherwise-healthy-adults.md)
- [Understanding Heart Health at Every Life Stage for Women](https://medichelpline.com/clinical-feed/aha-news-1-why-every-stage-of-life-matters-for-a-woman-s-heart-health.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.